Barclays’s Anebulo Pharmaceuticals ANEB Stock Holding History

Barclays’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-399	Closed	-$998	–	5218
2025 Q3	$998	Buy	+399	New	+$939	﹤0.01%	5178

Other funds holding ANEB

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's ANEB Position: Q4 2025 in Review

Barclays sold out of Anebulo Pharmaceuticals (ANEB) in Q4 2025, closing a stake of 399 shares — an estimated $998 sold.

Barclays first reported a position in ANEB in Q3 2025 and held it in 1 quarter. The position peaked at $998 in Q3 2025. 19 funds tracked by Wall St. Rank hold ANEB as of Q4 2025.

Barclays reported no remaining Anebulo Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Barclays sold 399 Anebulo Pharmaceuticals shares in Q4 2025, an estimated $998.
Barclays first reported a position in Anebulo Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Barclays's Anebulo Pharmaceuticals position peaked at $998 in Q3 2025.
19 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.